Evidence map›Paper›PMID 36003660›Full record

ArticleClinical kidney journal2022

The incidence of cancer recurrence and new cancer following commencement of dialysis.

Wai H Lim, Esther Ooi, Aashi Pankaj, Armando Teixeira-Pinto, Yingxin Lin, David W Johnson, Carmel M Hawley, Andrea K Viecelli, Helen Pilmore, Matthew A Roberts and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical kidney journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. CD71BMC nephrology · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 2 countries.

Wai H LimMedical School, University of Western Australia, Perth, Western Australia, Australia.
Esther OoiMedical School, University of Western Australia, Perth, Western Australia, Australia.
Aashi PankajSchool of Biomedical Sciences, University of Western Australia, Perth, Western Australia, Australia.
Armando Teixeira-PintoSchool of Public Health, Faculty of Medicine and Health, Sydney University, Sydney, New South Wales, Australia.
Yingxin LinSchool of Public Health, Faculty of Medicine and Health, Sydney University, Sydney, New South Wales, Australia.
David W JohnsonDepartment of Nephrology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.
Carmel M HawleyDepartment of Nephrology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.
Andrea K ViecelliDepartment of Nephrology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.
Helen PilmoreDepartment of Renal Medicine, Auckland City Hospital, Auckland, New Zealand.
Matthew A RobertsEastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.
Christopher E DaviesAustralia and New Zealand Dialysis and Transplant Registry, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
Anoushka KrishnanDepartment of Renal Medicine, Royal Perth Hospital, Perth, Westen Australia, Australia.
Germaine WongSchool of Public Health, Faculty of Medicine and Health, Sydney University, Sydney, New South Wales, Australia.
The University of Queensland · AUThe University of Western Australia · AUThe University of Sydney · AUMonash University · AURoyal Perth Hospital · AUSouth Australian Health and Medical Research Institute · AUUniversity of Auckland · NZWestmead Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with kidney failure have a higher cancer risk compared with the age-matched general population. However, the outcomes of incident dialysis patients with a prior cancer history are unknown. Methods: Using Australia and New Zealand Dialysis and Transplant Registry data (2000-2019), the outcomes and survival probabilities of incident dialysis patients with prior cancers and having experienced a cancer recurrence or having developed a new cancer after dialysis commencement were described. Results: Of 4912 patients with prior cancers before dialysis commencement, 323 (7%) and 343 (7%) patients experienced cancer recurrence or developed new cancers after dialysis initiation, respectively. The median time from dialysis commencement to cancer recurrence was 1.2 years [interquartile range (IQR) 0.5-2.8] and was 2.0 years (IQR 0.7-4.0) for new cancer occurrence. Of those with cancer recurrence, 80% presented with metastatic disease and one in two patients died from cancer, with a median time from cancer recurrence to death of 0.5 years (IQR 0.2-1.7). Of those who developed new cancer, urinary tract and respiratory cancers were the most frequent cancer types, with a median time from new cancer diagnosis to death of 1.3 years (IQR 0.4-3.1). The 3-year survival probabilities on dialysis following cancer recurrence and new cancer were 19% [95% confidence interval (CI) 15-24] and 41% (35-47), respectively. Conclusion: Among incident dialysis patients with a prior cancer history, 14% experienced cancer recurrence or developed a new cancer. Patients who experienced cancer recurrence or developed new cancer have poor outcomes, with ˂50% surviving beyond 3 years. These findings suggest the need to have a greater understanding of the characteristics, cancer screening, treatment responses and reasons for commencing dialysis in patients with kidney failure and prior cancer history, which may help in the shared clinical decision-making process when considering dialysis for these patients.

Indexed as

cancer mortalitycancer recurrencedialysismortalitynew cancerprior cancer

Identifiers

PMID36003660
PMCPMC9394713
OpenAlexW4281670826

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.